Skip to Content

MAGNAPEN 250MG/250MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION

Active substance(s): AMPICILLIN / FLUCLOXACILLIN

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Magnapen® 250mg/250mg Powder for Solution for Injection or Infusion
or
Co-fluampicil 250mg/250mg Powder for Solution for Injection or Infusion

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Co-fluampilcil 500mg Vials contain 250mg ampicillin as ampicillin sodium
with 250mg flucloxacillin as flucloxacillin sodium (co-fluampicil 250/250).

3

PHARMACEUTICAL FORM
Powder for Solution for Injection or Infusion (injection)

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Co-fluampicil is indicated for the treatment of severe infections where the
causative organism is unknown, and for mixed infections involving βlactamase-producing staphylococci. Typical indications include:
In general practice. Chest infections, ENT infections, skin and soft tissue
infections, and infections in patients whose underlying pathology places them
at special risk.
In hospital (prior to laboratory results being available): severe respiratory tract
infections, post-operative chest and wound infections, septic abortion,
puerperal fever; septicaemia, prophylaxis in major surgery, infections in
patients receiving immuno-suppressive therapy.
The spectrum of activity of co-fluampicil also makes it suitable for the
treatment of many mixed infections, particularly those where β -lactamaseproducing staphylococci are suspected or confirmed.
Parenteral usage is indicated where oral dosage is inappropriate.

4.2

Posology and method of administration
Usual adult dosage (including elderly patients and children over ten
years):
Intramuscular/Intravenous: 500mg four times a day.
Usual children’s dosage:
Intramuscular/intravenous: Under 2 years: quarter adult dose, four times a
day.
2-10 years: half adult dose, four times a day.
The above dosages for adults and children may be doubled where necessary.
Therapy may be continued for as long as it is indicated by the nature of
infection.
Administration:
Intramuscular: Add 1.5m1 Water for Injections BP to vial contents.
Intravenous: Dissolve 500mg in l0ml Water for Injections BP.
Administer by slow intravenous injection.
Co-fluampicil Injection may be added to infusion fluids or injected, suitably
diluted into the drip tube over a period of 3 - 4 minutes.

4.3

Contraindications
Co-fluampicil contains ainpicillin and flucloxacillin which are penicillins, and
should not be given to patients with a history of hypersensitivity to β-lactam
antibiotics (e.g. penicillins, cephalosporins).
Co-fluampicil is contraindicated in patients with a history of flucloxacillinassociated
jaundice/hepatic dysfunction.
Ocular administration.

4.4

Special warnings and precautions for use
Before initiating therapy with co-fluampicil careful enquiries should be made
concerning previous hypersensitivity reactions to β-lactam antibiotics.
Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have
been reported in patients receiving β-lactam antibiotics. Although anaphylaxis
is more frequent following parenteral therapy, it has occurred in patients on
oral therapy. These reactions are more likely to occur in individuals with
hypersensitivity to β-lactam antibiotics.

Co-fluampicil contains ampicillin and should be avoided if infectious
mononucleosis and/or acute or chronic leukaemia of lymphoid origin are
suspected. The occurrence of a skin rash has been associated with these
conditions following the administration of ampicillin.
In case of severe and persistent diarrhoea, the possibility of
pseudomembranous colitis should be considered; flucloxacillin therapy should
be discontinued.
Care is required when treating some patients with spirochaete infections such as
syphilis or leptospirosis because the Jarisch-Herxheimer reaction may occur
shortly after treatment with a penicillin is started.
Co-fluampicil should be used with caution in patients with evidence of hepatic
dysfunction (see Section 4.8).
Special caution is essential in the newborn because of the risk of
hyperbilirubinemia. Studies have shown that, at high dose following
parenteral administration, flucloxacillin can displace bilirubin from plasma
protein binding sites, and may therefore predispose to kernicterus in a
jaundiced baby. In addition, special caution is essential in the newborn
because of the potential for high serum levels of flucloxacillin due to a
reduced rate of renal excretion.
Care is necessary if very high doses of flucloxacillin are given, especially if renal
function is poor, because of the risk of nephrotoxicity and/or neurotoxicity. The
intrathecal route should be avoided. Care is also necessary if large doses of
sodium (salts) are given to patients with impaired renal function or heart failure.
Flucloxacillin should be used with caution in patients with evidence of hepatic
dysfunction (see section 4.8). Renal, hepatic and haematological status should
be monitored during prolonged and high-dose therapy (e.g. osteomyelitis,
endocarditis). Prolonged use may occasionally result in overgrowth of nonsusceptible organisms.
Sodium content: Co-fluampicil 500mg vials contains 29.9mg (1.3 mmol)
sodium per vial. This should be included in the daily allowance of patients on
sodium restricted diets.
4.5

Interaction with other medicinal products and other forms of interaction
Other antibacterials: There may be antagonism between penicillins, including
ampicillin and bacteriostatic agents such as chloramphenicol, erythromycins or
tetracyclines. This may reduce the effectiveness of penicillins particularly in
the treatment of infections such as pneumococcal meningitis and scarlet fever.
Cytotoxics: Penicillins reduce the excretion of methotrexate (increased risk of
toxicity).

In common with other oral broad-spectrum antibiotics, co-fluampicil may
reduce the efficacy of oral contraceptives and patients should be warned
accordingly.
Probenecid decreases the renal tubular secretion of co-fluampicil. Concurrent
use with co-fluampicil may result in increased and prolonged blood levels of
both ampicillin and flucloxacillin.
Concurrent administration of allopurinol during treatment with ampicillin can
increase the likelihood of allergic skin reactions.
Interference with diagnostic tests: Penicillins may produce false-positive
results with the direct antiglobulin (Coombs’) test, falsely high urinary glucose
results with the copper sulphate test and falsely high urinary protein results,
but glucose enzymatic tests (e.g. Clinistix) and bromophenol blue tests (e.g.
Multistix or Albustix) are not affected
4.6

Fertility, pregnancy and lactation
Pregnancy: Animal studies with co-fluampicil have shown no teratogenic
effects. The product has been in clinical use since 1971 and the limited
number of reported cases of use in human pregnancy have shown no evidence
of untoward effects. The decision to administer any drug during pregnancy
should be taken with the utmost care. Therefore co-fluampicil should only be
used in pregnancy when the potential benefits outweigh the potential risks
associated with treatment.
Lactation: Trace quantities of ampicillin and flucloxacillin can be detected in
breast milk. The possibility of hypersensitivity reactions must be considered
in breast-fed infants. Therefore co-fluampicil should only be administered to a
breast-feeding mother when the potential benefit outweigh the potential risks
associated with treatment.

4.7

Effects on ability to drive and use machines
Adverse effects on the ability to drive or operate machinery have not been
observed.

4.7

Undesirable effects
Blood and lymphatic system disorders:
As with other β-lactam antibiotics haematological effects including reversible
leucopenia, reversible thrombocytopenia and haemolytic anaemia have been
reported rarely.
Immune System Disorders:
Anaphylaxis (see Item 4.4-warnings) has been reported rarely.
If any hypersensitivity reaction occurs, the treatment should be discontinued.

Late sensitivity reactions may include serum sickness-like reactions (featuring
symptoms such as arthralgia, rash, urticaria, fever, angioedema,
lymphadenopathy), haemolytic anaemia and acute interstitial nephritis.
Metabolism and nutrition disorders:
Electrolyte disturbances, such as hypokalaemia, due to administration of large
amounts of sodium
Psychiatric disorders:
There is a potential for hallucinations to occur rarely with flucloxacillin.
Nervous System Disorders
Convulsions may be associated with IV administration of high doses to
patients with underlying renal failure.
Coma may develop with high doses of Flucloxacillin.
Respiratory, thoracic and mediastinal disorders:
Bronchospasm may occur as a result of penicillin allergy.
There is a potential for acute, severe dyspnoea to occur with flucloxacillin.
Gastrointestinal disorders:
Minor gastrointestinal disturbances, including occasionally nausea, vomiting
and diarrhoea may occur during treatment. Pseudomembranous colitis has
been reported rarely.
Hepatobiliary disorders:
Hepatitis and cholestatic jaundice have been reported rarely. These may be
delayed for up to two months after withdrawal of treatment. In some cases the
course of these conditions has been protracted and lasted for several months.
Very rarely deaths have been reported from hepatic effects but are mostly
limited to patients with serious underlying disease.
As with most other antibiotics, a moderate transient increase in transaminases
has been reported.

Skin and subcutaneous tissue disorders:
Skin rash, puritis and urticaria have been reported. The incidence of rash is
higher in patients suffering from infectious mononucleosis and acute or
chronic leukaemia of lymphoid origin. Purpura, fever, eosinophilia and
sometimes angioneurotic oedema have also been reported. Rarely, skin
reactions such as erythema multiforme, Stevens-Johnson syndrome, and toxic
epidermal necrolysis have been reported. Reactions such as fever, arthralgia,
and myalgia can develop more than 48 hours after the start of the treatment.
Erythema nodosum may occur rarely with flucloxacillin.
Potential for pemphigoid reactions to occur rarely with flucloxacillin.
There is potential for non-thrombocytopenic purpura to occur rarely with
flucloxacillin.
Vasculitis may occur rarely with flucloxacillin.

Renal and urinary disorders
Interstitial nephritis may occur but it is reversible when treatment is
discontinued.
Congenital, familial and genetic disorders:
Potential for acute attacks of porphyria to occur with flucloxacillin.
General disorders and administration site conditions:
Some patients with spirochaete infections such as syphilis or leptospirosis may
experience a Jarisch-Herxheimer reaction shortly after treatment with a
penicillin is started. Symptoms include fever, chills, headache and reaction at
the site of lesions. The reaction can be dangerous in cardiovascular syphilis or
where there is a serious risk of increased local damage such as with optic
atrophy
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at
www.mhra.gov.uk/yellowcard.
4.9

Overdose
Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident
and should be treated symptomatically.
Co-fluampicil contains flucloxacillin. Haemodialysis does not lower the serum
levels of flucloxacillin.

Co-fluampicil contains ampicillin, which may be removed from the circulation by
haemodialysis

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Co-fluampicil is indicated for the treatment of severe infections where the
causative organism is unknown, and for mixed infections involving βlactamase-producing staphylococci.

5.2

Pharmacokinetic properties

Co-fluampicil is excreted via the kidneys with a plasma half life of
approximately one hour.

5.3

Preclinical safety data
Not relevant

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
None

6.2.

Incompatibilities
Co-fluampicil should not be mixed with blood products or other proteinaceous fluids
(e.g. protein hydrolysates) or with intravenous lipid emulsions.
If co-fluampicil is prescribed concurrently with an aminoglycoside, the antibiotics
should not be mixed in the syringe, intravenous fluid container or giving set because
of loss of activity of the aminoglycoside can occur under these conditions.
The following drugs are incompatible with Magnapen® 250mg/250mg Powder for
Solution for Injection or Infusion or Co-fluampicil 250mg/250mg Powder for
Solution for Injection or Infusion:
Amikacin sulphate
Amiodarone
Amphotericin B cholesteryl sulphate complex
Atropine Sulphate
Buprenorphine
Calcium gluconate
Chlorpromazine hydrochloride
Ciprofloxacin
Clarithromycin
Diazepam
Dobutamine Hydrochloride
Dopamine hydrochloride
Erythromycin lactobionate
Gentamicin sulphate
Heparin sodium
Hydralazine hydrochloride
Hydrocortisone sodium succinate
Kanamycin sulphate
Lincomycin hydrochloride

Morphine Sulphate
Metoclopramide hydrochloride
Netilmicin Sulphate
Ofloxacin
Papaveretum
Pethidine Hydrochloride
Polymyxin B sulphate
Prochlorperazine edisylate
Prochlorperazine mesylate
Promethazine Hydrochloride
Sodium bicarbonate
Tobramycin
Verapamil Hydrochloride

6.3

Shelf life
Three years.
See also Section 6.6.

6.4

Special precautions for storage
Co-fluampicil Vials for Injection should be stored in a dry place at, or below
25ºC.

6.5

Nature and contents of container
5 or 10 ml glass vials fitted with butyl rubber disc and an aluminium seal.
Boxes of 10 vials with instructions for use.

6.6

Special precautions for disposal
Co-fluampicil solutions for injection should be used immediately. Cofluampicil may be added to most intravenous fluids (e.g. Water for Injections,
sodium chloride 0.9%, glucose 5%, sodium chloride 0.18% with glucose 4%).
In intravenous solutions containing glucose or other carbohydrates, cofluampicil should be infused within two hours of preparation. Intravenous
solutions of co-fluampicil in Water for Injections or sodium chloride 0.9%
should be infused within 24 hours of preparation. Full particulars are given in
the package enclosure leaflet. Preparation of co-fluampicil infusion solutions
must be carried out under appropriate aseptic conditions if these extended
storage periods are required.

7

MARKETING AUTHORISATION HOLDER

Wockhardt UK Ltd
Ash Road North
Wrexham LL13 9UF
United Kingdom

8

MARKETING AUTHORISATION NUMBER(S)
PL 29831/0054

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
18th June 2007

10

DATE OF REVISION OF THE TEXT
10/03/2016

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide